Literature DB >> 10466819

Epstein-Barr virus lacking latent membrane protein 2 immortalizes B cells with efficiency indistinguishable from that of wild-type virus.

Peter Speck1, Kimberly A Kline1, Paul Cheresh1, Richard Longnecker1.   

Abstract

Epstein-Barr virus (EBV) is a human herpesvirus that efficiently transforms and immortalizes human primary B lymphocytes. In this study, the role of latent membrane protein 2 (LMP2) in EBV growth transformation was investigated. LMP2 is a virally encoded membrane protein expressed in EBV-immortalized B cells previously shown to be nonessential for EBV transformation. However, a recent study reported that LMP2 may be an important determinant for efficient B cell transformation (Brielmeier et al., Journal of General Virology 77, 2807-2818, 1996). In this study a deletion mutation was introduced into the LMP2 gene using an E. coli mini-EBV construct containing sufficient EBV DNA to result in growth transformation of primary B cells. In an alternative approach, the introduction of the gene encoding the enhanced green fluorescent protein (EGFP) by homologous recombination into the LMP2 gene of EBV strain B95-8, generating the same LMP2 deletion mutation is reported. Careful quantification of B cell transformation using the EGFP+ LMP2- recombinant virus determined that in liquid culture medium or in culture medium containing soft agarose there was no difference in the ability of LMP2- virus to immortalize primary human B cells when compared to that of wild-type virus.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10466819     DOI: 10.1099/0022-1317-80-8-2193

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  33 in total

1.  Epstein-Barr virus entry utilizing HLA-DP or HLA-DQ as a coreceptor.

Authors:  K M Haan; W W Kwok; R Longnecker; P Speck
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

Review 2.  The genetic approach to the Epstein-Barr virus: from basic virology to gene therapy.

Authors:  H J Delecluse; W Hammerschmidt
Journal:  Mol Pathol       Date:  2000-10

3.  Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-Kinase/Akt pathway.

Authors:  R Swart; I K Ruf; J Sample; R Longnecker
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

4.  PY motifs of Epstein-Barr virus LMP2A regulate protein stability and phosphorylation of LMP2A-associated proteins.

Authors:  M Ikeda; A Ikeda; R Longnecker
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

Review 5.  NF-κB as a target for oncogenic viruses.

Authors:  Shao-Cong Sun; Ethel Cesarman
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

6.  Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival.

Authors:  Christoph Mancao; Wolfgang Hammerschmidt
Journal:  Blood       Date:  2007-08-06       Impact factor: 22.113

7.  Minimal protein domain requirements for the intracellular localization and self-aggregation of Epstein-Barr virus latent membrane protein 2.

Authors:  Monica Jo Tomaszewski-Flick; David T Rowe
Journal:  Virus Genes       Date:  2007-06-13       Impact factor: 2.332

Review 8.  The role of Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma.

Authors:  Chi Man Tsang; Sai Wah Tsao
Journal:  Virol Sin       Date:  2015-04-21       Impact factor: 4.327

9.  Augmented latent membrane protein 1 expression from Epstein-Barr virus episomes with minimal terminal repeats.

Authors:  Allison M Repic; Mingxia Shi; Rona S Scott; John W Sixbey
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

10.  Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma.

Authors:  Qing-Li Kong; Li-Juan Hu; Jing-Yan Cao; Yi-Jun Huang; Li-Hua Xu; Yi Liang; Dan Xiong; Su Guan; Bao-Hong Guo; Hai-Qiang Mai; Qiu-Yan Chen; Xing Zhang; Man-Zhi Li; Jian-Yong Shao; Chao-Nan Qian; Yun-Fei Xia; Li-Bing Song; Yi-Xin Zeng; Mu-Sheng Zeng
Journal:  PLoS Pathog       Date:  2010-06-03       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.